Citadel Advisors
NVNO

Citadel Advisors’s enVVeno Medical NVNO Stock Holding History

Citadel Advisors’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-397
Closed -$36.6K – 14274
2025
Q1 		$36.6K Sell
397
-614
-61% -$68.4K ﹤0.01% 12624
2024
Q4 		$107K Buy
1,011
+25
+3% +$2.79K ﹤0.01% 11381
2024
Q3 		$116K Sell
986
-83
-8% -$15.2K ﹤0.01% 10926
2024
Q2 		$196K Sell
1,069
-340
-24% -$59.3K ﹤0.01% 9972
2024
Q1 		$268K Buy
1,409
+780
+124% +$140K ﹤0.01% 9713
2023
Q4 		$113K Buy
+629
New +$100K ﹤0.01% 10772
2023
Q3 		– Sell
-151
Closed -$16.3K – 14831
2023
Q2 		$16.3K Buy
+151
New +$19.6K ﹤0.01% 12900
2023
Q1 		– Sell
-191
Closed -$34.2K – 15250
2022
Q4 		$34.2K Sell
191
-1,226
-87% -$249K ﹤0.01% 12591
2022
Q3 		$311K Buy
1,417
+771
+119% +$164K ﹤0.01% 9490
2022
Q2 		$85K Sell
646
-428
-40% -$66.4K ﹤0.01% 11553
2022
Q1 		$240K Sell
1,074
-583
-35% -$113K ﹤0.01% 11104
2021
Q4 		$382K Sell
1,657
-12
-0.7% -$3.38K ﹤0.01% 10340
2021
Q3 		$606K Buy
+1,669
New +$432K ﹤0.01% 9397

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's NVNO Position: Q1 2026 in Review

Citadel Advisors sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 1,221 shares — an estimated $13.7K sold.

Citadel Advisors first reported a position in NVNO in Q4 2018 and held it in 15 quarters. The position peaked at $321K in Q4 2024. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • Citadel Advisors reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,221 enVVeno Medical shares in Q1 2026, an estimated $13.7K.
  • Citadel Advisors first reported a position in enVVeno Medical in Q4 2018 and held it in 15 quarters.
  • Citadel Advisors's enVVeno Medical position peaked at $321K in Q4 2024.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.